A biomarker of collagen type I degradation is associated with cardiovascular events and mortality in patients with atherosclerosis

被引:19
作者
Nielsen, S. Holm [1 ,2 ]
Tengryd, C. [3 ]
Edsfeldt, A. [3 ,4 ]
Brix, S. [2 ]
Genovese, F. [1 ]
Bengtsson, E. [3 ]
Karsdal, M. [1 ]
Leeming, D. J. [1 ]
Nilsson, J. [3 ]
Goncalves, I. [3 ,4 ]
机构
[1] Nord Biosci, Herlev Hovedgade 205-207, DK-2730 Herlev, Denmark
[2] Tech Univ Denmark, Lyngby, Denmark
[3] Lund Univ, Expt Cardiovasc Res Unit, Malmo, Sweden
[4] Skane Univ Hosp, Dept Cardiol, Malmo, Sweden
基金
瑞典研究理事会;
关键词
atherosclerosis; biomarkers; collagen; extracellular matrix; inflammation; MATRIX-METALLOPROTEINASES;
D O I
10.1111/joim.12819
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Atherosclerosis is characterized by accumulation of lipids, cells and extracellular matrix (ECM) proteins in the arterial wall. Collagen type I (COL1), a component of the arterial ECM, is cleaved by matrix metalloproteinases (MMPs) and known to be remodelled in atherosclerosis. We explored whether the MMP-mediated COL1 biomarker, C1M, was associated with cardiovascular events, cardiovascular mortality and all-cause mortality in a large prospective cohort of patients with known atherosclerosis. Methods Serum from 787 patients who underwent a carotid endarterectomy was included. Circulating levels of C1M were measured in serum. A total of 473 patients were followed for 6 years after surgery. Associations between C1M and incidence of cardiovascular events, cardiovascular mortality and all-cause mortality were assessed by Kaplan-Meier curves and Cox regression analysis. Results A total of 101 (21.4%) patients suffered from nonfatal cardiovascular events during the follow-up period, and 64 (13.5%) patients died. Of these, 39 (60.9%) died from cardiovascular diseases. Patients with C1M levels above the median were significantly associated with cardiovascular events, cardiovascular mortality and all-cause mortality (P < 0.001, P = 0.004 and P < 0.001, respectively). C1M was included in the final model for prediction of cardiovascular events (HR 2.15, 95% CI 1.40-3.32, P = 0.001), cardiovascular mortality (HR 2.20, 95% CI 1.07-4.51, P = 0.031) and all-cause mortality (HR 2.98 95% CI 1.67-5.33, P = < 0.001). Conclusions In patients with atherosclerotic carotid lesions, high levels of C1M predicted cardiovascular events, cardiovascular mortality and all-cause mortality. These findings emphasize the importance of remodelling mechanisms in atherosclerosis that are now becoming more and more explored.
引用
收藏
页码:118 / 123
页数:6
相关论文
共 20 条
[1]   Collagens in the progression and complications of atherosclerosis [J].
Adiguzel, Eser ;
Ahmad, Pamela J. ;
Franco, Christopher ;
Bendeck, Michelle P. .
VASCULAR MEDICINE, 2009, 14 (01) :73-89
[2]  
[Anonymous], LANCET, DOI DOI 10.1161/CIR.0000000000000351
[3]  
Bertelsen DM, 2018, SCI REP, V8, P1
[4]   Usefulness of Plasma Matrix Metalloproteinase-3 Levels to Predict Myocardial Infarction in Men With and Without Acute Coronary Syndrome [J].
Cavusoglu, Erdal ;
Marmur, Jonathan D. ;
Kassotis, John T. ;
Yanamadala, Sunitha ;
Chopra, Vineet ;
Eng, Calvin .
AMERICAN JOURNAL OF CARDIOLOGY, 2016, 117 (06) :881-886
[5]   Quantitation and localization of matrix metalloproteinases and their inhibitors in human carotid endarterectomy tissues [J].
Choudhary, Salman ;
Higgins, Catherine L. ;
Chen, Iou Yih ;
Reardon, Michael ;
Lawrie, Gerald ;
Vick, G. Wesley, III ;
Karmonik, Christof ;
Via, David P. ;
Morrisett, Joel D. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (10) :2351-2358
[6]   Impaired Fibrous Repair A Possible Contributor to Atherosclerotic Plaque Vulnerability in Patients With Type II Diabetes [J].
Edsfeldt, Andreas ;
Goncalves, Isabel ;
Grufman, Helena ;
Nitulescu, Mihaela ;
Duner, Pontus ;
Bengtsson, Eva ;
Mollet, Ines G. ;
Persson, Ana ;
Nilsson, Marie ;
Orho-Melander, Marju ;
Melander, Olle ;
Bjorkbacka, Harry ;
Nilsson, Jan .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2014, 34 (09) :2143-2150
[7]   Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability [J].
Johnson, Jason L. ;
Fritsche-Danielson, Regina ;
Behrendt, Margareta ;
Westin-Eriksson, Annika ;
Wennbo, Hakan ;
Herslof, Margareta ;
Elebring, Marie ;
George, Sarah J. ;
McPheat, William L. ;
Jackson, Christopher L. .
CARDIOVASCULAR RESEARCH, 2006, 71 (03) :586-595
[8]   Metalloproteinases in atherosclerosis [J].
Johnson, Jason L. .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2017, 816 :93-106
[9]   COLLAGENS IN HUMAN ATHEROSCLEROSIS - IMMUNOHISTOCHEMICAL ANALYSIS USING COLLAGEN TYPE-SPECIFIC ANTIBODIES [J].
KATSUDA, S ;
OKADA, Y ;
MINAMOTO, T ;
ODA, Y ;
MATSUI, Y ;
NAKANISHI, I .
ARTERIOSCLEROSIS AND THROMBOSIS, 1992, 12 (04) :494-502
[10]   A novel marker for assessment of liver matrix remodeling: An enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M) [J].
Leeming, D. J. ;
He, Y. ;
Veidal, S. S. ;
Nguyen, Q. H. T. ;
Larsen, D. V. ;
Koizumi, M. ;
Segovia-Silvestre, T. ;
Zhang, C. ;
Zheng, Q. ;
Sun, S. ;
Cao, Y. ;
Barkholt, V. ;
Hagglund, P. ;
Bay-Jensen, A. C. ;
Qvist, P. ;
Karsdal, M. A. .
BIOMARKERS, 2011, 16 (07) :616-628